CTi Biopharma Corp

Company Profile

CTi Biopharma Corp had its IPO on 1997-03-21 under the ticker symbol CTIC.

The company operates in the Healthcare sector and Biotechnology industry. CTi Biopharma Corp has a staff strength of 127 employees.

Stock update

Shares of CTi Biopharma Corp opened at $9.1 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $9.09 - $9.1, and closed at $9.09.

This is a 0% increase from the previous day's closing price.

A total volume of 11,217,834 shares were traded at the close of the day’s session.

In the last one week, shares of CTi Biopharma Corp have increased by +0.22%.

CTi Biopharma Corp's Key Ratios

CTi Biopharma Corp has a market cap of $1.19 billion, indicating a price to book ratio of 112.6329 and a price to sales ratio of 22.0081.

In the last 12-months CTi Biopharma Corp’s revenue was $75.77 million with a gross profit of $50.43 million and an EBITDA of $-53565000. The EBITDA ratio measures CTi Biopharma Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, CTi Biopharma Corp’s operating margin was -73.54% while its return on assets stood at -28.58% with a return of equity of -1018.75%.

In Q1, CTi Biopharma Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 950.8%.

CTi Biopharma Corp’s PE and PEG Ratio

Forward PE

26.5957

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.54 per share while it has a forward price to earnings multiple of 26.5957 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CTi Biopharma Corp’s profitability.

CTi Biopharma Corp stock is trading at a EV to sales ratio of 20.1729 and a EV to EBITDA ratio of -6.6763. Its price to sales ratio in the trailing 12-months stood at 22.0081.

CTi Biopharma Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$112.27 million

Total Liabilities

$68.23 million

Operating Cash Flow

$15.26 million

Capital Expenditure

$0

Dividend Payout Ratio

0%

CTi Biopharma Corp ended 2024 with $112.27 million in total assets and $0 in total liabilities. Its intangible assets were valued at $112.27 million while shareholder equity stood at $-25347000.00.

CTi Biopharma Corp ended 2024 with $0 in deferred long-term liabilities, $68.23 million in other current liabilities, 132000.00 in common stock, $-2532329000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $24.21 million and cash and short-term investments were $59.01 million. The company’s total short-term debt was $48,895,000 while long-term debt stood at $0.

CTi Biopharma Corp’s total current assets stands at $86.45 million while long-term investments were $0 and short-term investments were $34.80 million. Its net receivables were $22.96 million compared to accounts payable of $2.03 million and inventory worth $777000.00.

In 2024, CTi Biopharma Corp's operating cash flow was $15.26 million while its capital expenditure stood at $0.

Comparatively, CTi Biopharma Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$9.09

52-Week High

$9.06

52-Week Low

$4.01

Analyst Target Price

$10.49

CTi Biopharma Corp stock is currently trading at $9.09 per share. It touched a 52-week high of $9.06 and a 52-week low of $9.06. Analysts tracking the stock have a 12-month average target price of $10.49.

Its 50-day moving average was $7.44 and 200-day moving average was $5.87 The short ratio stood at 0.78 indicating a short percent outstanding of 0%.

Around 549.7% of the company’s stock are held by insiders while 8328.5% are held by institutions.